- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
TREATING LIFE
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 68 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove excessive cytokines and other inflammatory mediators from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents specializes in treating life-threatening conditions in the ICU and during open heart surgery. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms
- CytoSorbents Reports Second Quarter 2022 Financial and Operational Results
- CytoSorbents to Report Second Quarter 2022 Operating and Financial Results
- The 2022 CytoSorb World Users' Meeting Highlights the Broad Market Potential of CytoSorb as an Interdisciplinary Therapeutic Approach
- Leading Critical Care and Cardiac Surgery Specialists from 40 Countries Meet to Discuss CytoSorb and the New Dimension in Blood Purification
- slider1.jpg
